SSY Group Wins Bids for 13 Products in China's National Drug Procurement Program

MT Newswires Live08-04 18:28

SSY Group's (HKG:2005) 13 products covering 16 specifications were selected in the 12th round of China's National Centralised Medicines Procurement program.

The selected products include Blonanserin Tablets, Vitamin B6 Injection, Acipimox Capsules, Doxazosin Mesylate Extended Release Tablets, Bumetanide Injection, Pentoxifylline Sustained-release Tablets, Deferasirox Dispersible Tablets and Calcium Chloride Injection, among others, according to a Hong Kong bourse filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment